Gynecologic Cancer Drugs in the Pipeline

Gynecologic Cancer Drugs in the Pipeline

36
HemOnc today | JUNE 10, 2016 | Healio.com/HemOnc
Gynecologic Cancer Drugs in the Pipeline
HemOnc Today presents this guide to drugs in phase 2 or phase 3 development for gynecologic cancer. Clinicians can use this chart as a quick reference to learn about the status of
those drugs that may be clinically significant to their practice.
Generic name (Brand name, Manufacturer) Indication(s)
Development status
3377794 (GlaxoSmithKline)
ovarian cancer
phase 2
AL3818 (Advenchen Laboratories)
ovarian cancer
phase 2
alisertib (Takeda)
ovarian cancer
phase 2
avelumab (PF-06834635/MSB0010718C; Pfizer, EMD Serono)
ovarian cancer (platinum-resistant refractory disease)
phase 3
axalimogene filolisbac (Advaxis)
cervical cancer (combination therapy
phase 2
cervical cancer (monotherapy)
phase 3
AZD1775 (AstraZeneca)
ovarian cancer
phase 2
BB503 (Boston Biomedical)
ovarian cancer
phase 2
bevacizumab (Avastin, Genentech)
ovarian cancer
phase 3
binimetinib (MEK162, Array BioPharma)
fallopian tube cancer, ovarian cancer, peritoneal cancer
phase 3
cediranib (AstraZeneca)
ovarian cancer (platinum-sensitive relapsed disease)
phase 3
cositecan (Karenitecin, BioNumerik Pharmaceuticals)
ovarian cancer
phase 3
cridanimod (Kevelt and Pharmsynthez)
endometrial cancer
phase 2
CRLX101 (Cerulean Pharma)
ovarian cancer
phase 2
demcizumab (OncoMed Pharmaceuticals)
ovarian cancer (platinum-resistant disease)
phase 2
DPX-Survivac (Immunovaccine)
fallopian tube cancer, ovarian cancer, peritoneal cancer
phase 2
ENMD-2076 (CASI Pharmaceuticals)
ovarian clear cell carcinoma
phase 2
EP-100 (Esperance Pharmaceuticals)
endometrial cancer, ovarian cancer
phase 2
epacadostat (INCB024360, Incyte)
fallopian tube cancer, ovarian cancer, peritoneal cancer
phase 2
etirinotecan pegol (NKTR-102, Nektar Therapeutics)
ovarian cancer
phase 2
farletuzumab (MORAb-003, Eisai)
ovarian cancer (platinum-sensitive disease)
phase 2
fosbretabulin (CA4P, Oxigene)
ovarian cancer (recurrent disease)
phase 2
ovarian cancer (combination therapy for platinum-resistant
disease)
phase 3
GALE-301 (Galena Biopharma)
endometrial cancer, ovarian cancer
phase 2
ganetespib (Synta Pharmaceuticals)
ovarian cancer (platinum-resistant, p53-mutant disease)
phase 2
GEN-1 (Celsion)
ovarian cancer
phase 2
guadecitabine (Otsuka)
ovarian cancer
phase 2
lenvatinib (Lenvima, Eisai)
endometrial cancer
phase 2
lurbinectedin (PM1183, PharmaMar)
ovarian cancer (second-line or third-line treatment for platinumresistant disease)
phase 3
LY2606368 (Eli Lilly)
ovarian cancer
phase 2
mirvetuximab soravtansine (Immunogen)
ovarian cancer
phase 2
motolimod (VTX-2337, VentiRx Pharmaceuticals)
ovarian cancer (combination therapy)
phase 2
napabucasin (BB608, Boston Biomedical)
ovarian cancer
phase 2
NGR-hTNF (MolMed)
ovarian cancer (combination therapy for advanced or metastatic
disease; combination therapy for platinum-resistant disease)
phase 2
nintedanib (Vargatef, Boehringer Ingelheim)
fallopian tube cancer, ovarian cancer, peritoneal cancer
phase 2
niraparib (Tesaro)
ovarian cancer
phase 3
NY-ESO-1/LAGE-1–specific T cells (Adaptimmune)
ovarian cancer
phase 2
olaparib (Lynparza, AstraZeneca)
ovarian cancer
phase 3
oregovomab (Quest PharmaTech)
ovarian cancer (combined with chemotherapy for advanced
disease)
phase 2
paclitaxel poliglumex (CTI BioPharma)
ovarian cancer (first-line maintenance)
phase 3
pelareorep (Reolysin, Oncolytics Biotech)
fallopian tube cancer, ovarian cancer, primary peritoneal cancer
phase 2
pentavalent vaccine (MabVax Therapeutics)
ovarian cancer
phase 2
ralimetinib (LY2228820, Eli Lilly)
ovarian cancer
phase 2
rucaparib (Clovis)
ovarian cancer
phase 2
gynecologic cancers (combination therapy), ovarian cancer
(maintenance)
phase 3
S-1 (Taiho Pharmaceuticals)
cervical cancer (stage IVb, recurrent or persistent disease)
phase 3
selinexor (Karyopharm)
gynecologic malignancies
phase 2
SGI-110 (Astex Pharmaceuticals)
ovarian cancer
phase 2
TAK-228 (Takeda)
endometrial cancer
phase 2
TPIV 200 (TapImmune)
ovarian cancer (combination therapy for platinum-resistant
disease)
phase 2
trabectedin (Yondelis, Janssen)
ovarian cancer (relapsed disease)
phase 3
trebananib (AMG 386, Amgen)
fallopian tube cancer, ovarian cancer, primary peritoneal cancer
phase 3
37
HemOnc today | JUNE 10, 2016 | Healio.com/HemOnc
Gynecologic Cancer Drugs in the Pipeline
Generic name (Brand name, Manufacturer) Indication(s)
Development status
triapine (Nanotherapeutics and NCI)
cervical cancer, vaginal cancer
phase 2
VB-111 (Vascular Biogenics Ltd.)
ovarian cancer (recurrent platinum-resistant disease)
phase 2
veliparib (AbbVie)
ovarian cancer
phase 3
VGX-3100 (Inovio)
cervical dysplasia
phase 2
Vigil (Gradalis)
ovarian cancer
phase 3
zoptarelin doxorubicin (Zoptrex, Æterna Zentaris)
ovarian cancer
phase 2
endometrial cancer
phase 3
Information in this chart was compiled from the Pharmaceutical Research and Manufacturers of America, NIH (www.clinicaltrials.gov), corporate websites and the databases of HemOnc Today. The
publisher or editors do not assume responsibility for any errors or omissions.